< Back to previous page
Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 59
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Feb 2023 → TodayFunding: BOF - projects
- Characterization of triggers of post-operative recurrence in Crohn’s disease in both the external and luminal side of the intestineFrom1 Jan 2023 → TodayFunding: FWO research project
- Development of a gut-on-a-chip model for pre-clinical testing of drugs for inflammatory bowel diseaseFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Host-microbe interaction in intestinal homeostasis: unravelling the mechanisms involved in the onset of multiple inflammationrelated diseasesFrom1 Jan 2022 → TodayFunding: FWO EOS
- Artificial intelligence and data integration to achieve improved outcomes and personalised healthcare in IBDFrom1 Oct 2021 → 15 Oct 2021Funding: FWO junior postdoctoral fellowship
- Lipidomic, microbial and functional characterization of triggers of post-operative recurrence in Crohn’s diseaseFrom1 Oct 2021 → TodayFunding: FWO junior postdoctoral fellowship
- Histological healing in inflammatory bowel diseaseFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- A novel molecular and personalized prognostic and predictive approach to inflammatory bowel diseasesFrom1 Oct 2021 → TodayFunding: BOF - ZAP BOF mandates
- The role of lipidomics in early postoperative Crohn’s recurrence.From14 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 812
- Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease(2023)
Authors: Bram Verstockt, Séverine Vermeire, Debby Thomas, Paul Declerck
Pages: 838 - + - Evaluating the potential of artificial intelligence in ulcerative colitis(2023)
Authors: Pieter Sinonquel, Bram Verstockt, Séverine Vermeire, Raf Bisschops
Pages: 145 - 153 - Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD(2023)
Authors: Bram Verstockt, Sare Verstockt, Marc Ferrante, Séverine Vermeire
- Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives.(2023)
Authors: Judith Wellens, Eva Vissers, Christophe Matthys, Séverine Vermeire, João Pedro Guedelha Sabino
Pages: 15 - 27 - Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial(2023)
Authors: Marc Ferrante, Séverine Vermeire
Pages: 138 - 147 - Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial(2023)
Authors: Séverine Vermeire
Pages: 43 - 55 - Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib(2023)
Authors: Séverine Vermeire
Pages: 85 - 96 - Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program(2023)
Authors: Séverine Vermeire
Pages: 27 - 41 - Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission(2023)
Authors: Séverine Vermeire
- Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?(2023)
Authors: Judith Wellens, Bram Verstockt, Marc Ferrante, Séverine Vermeire
Pages: 192 - 204
Patents
1 - 10 of 10
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)
- MUCOSAL GENE SIGNATURES (Inventor)